The Idiopathic Interstitial Pneumonias and Connective Tissue Disease-Associated Interstitial Lung Disease

被引:3
|
作者
Swigris, Jeffrey J. [1 ,2 ]
Brown, Kevin K. [1 ,2 ]
Flaherty, Kevin R. [3 ]
机构
[1] Natl Jewish Hlth, Autoimmune Lung Ctr, Denver, CO USA
[2] Natl Jewish Hlth, Interstitial Lung Dis Program, Denver, CO USA
[3] Univ Michigan Hlth Syst, Div Pulm & Crit Care Med, 1500 E Med Ctr Dr,3916 Taubman Ctr, Ann Arbor, MI 48109 USA
关键词
Connective tissue disease; idiopathic; bronchiolitis;
D O I
10.2174/157339710791330731
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The idiopathic interstitial pneumonias (IIP) are seven fibro-inflammatory interstitial lung diseases of unknown cause, grouped together because of potentially similar clinical features. Each of the seven has a distinct histologic pattern; however, these patterns are not specific to the IIP, and they provide a framework for defining interstitial lung disease (ILD) of known-cause, including ILD associated with underlying connective tissue disease (CTD). With the exception of respiratory bronchiolitis, the histologic patterns corresponding with the other six IIP can be found in association with CTD. Considering all CTD together, the pattern of non-specific interstitial pneumonia is most common. High-resolution computed tomography (HRCT) can hint at the histologic pattern, track changes over time, and assess response to therapy. The goal of this article is to review histologic patterns and HRCT findings of the IIP as they relate to CTD-associated ILD.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 50 条
  • [21] Connective tissue disease-associated interstitial lung disease: a review
    Markus Gutsche
    Glenn D. Rosen
    Jeffrey J. Swigris
    Current Respiratory Care Reports, 2012, 1 (4): : 224 - 232
  • [22] Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
    Barnes, Hayley
    Holland, Anne
    Westall, Glen
    Glaspole, Ian
    CHEST, 2017, 152 (04) : 442A - 442A
  • [23] Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
    Boerner, Eda B.
    Cuyas, Marta
    Theegarten, Dirk
    Ohshimo, Shinichiro
    Costabel, Ulrich
    Bonella, Francesco
    RESPIRATION, 2020, 99 (08) : 628 - 636
  • [24] Treatment approach to connective tissue disease-associated interstitial lung disease
    Wilson, Timothy M.
    Solomon, Joshua J.
    Demoruelle, M. Kristen
    CURRENT OPINION IN PHARMACOLOGY, 2022, 65
  • [25] Connective Tissue Disease-Associated Interstitial Lung Disease A Call for Clarification
    Fischer, Aryeh
    West, Sterling G.
    Swigris, Jeffrey J.
    Brown, Kevin K.
    du Bois, Roland M.
    CHEST, 2010, 138 (02) : 251 - 256
  • [26] Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease
    Vij, Rekha
    Strek, Mary E.
    CHEST, 2013, 143 (03) : 814 - 824
  • [27] RITUXIMAB FOR THE TREATMENT OF CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Chartrand, Sandra
    Swigris, Jeffrey J.
    Peykova, Lina
    Fischer, Aryeh
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2015, 32 (04) : 296 - 304
  • [28] Updates in the management of connective tissue disease-associated interstitial lung disease
    Kavadichanda, Chengappa
    Naidu, G. S. R. S. N. K.
    INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (05) : 109 - 115
  • [29] A Clue to Diagnosing Connective Tissue Disease-Associated Interstitial Lung Disease
    Teramoto, Shinji
    Komiya, Kosaku
    Akashi, Shunsuke
    Kawashima, Masahiro
    CHEST, 2011, 139 (03) : 722 - 722
  • [30] Rituximab in autoimmune connective tissue disease-associated interstitial lung disease
    Sharp, Charles
    McCabe, Melanie
    Dodds, Nick
    Edey, Anthony
    Mayers, Lloyd
    Adamali, Huzaifa
    Millar, Ann B.
    Gunawardena, Harsha
    RHEUMATOLOGY, 2016, 55 (07) : 1318 - 1324